D-1391-2020 Class III Terminated
FDA drug recall D-1391-2020 was initiated by Fresenius Kabi USA, LLC on Jul 13, 2020 and is designated Class III. Reason for recall: Labeling Error: Label Error on Declared Strength: Carton label and product insert incorrectly states the quantity of the excipient edetate disodium (EDTA) as 5.4 mg / vial, rather than the actual… The recall status is terminated (terminated Aug 19, 2022). Affected quantity: 63,067 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 22, 2020
- Initiation Date
- Jul 13, 2020
- Termination Date
- Aug 19, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 63,067 vials
Product description
Fosaprepitant for Injection, 150 mg / vial in a 10 mL Single-Dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047; NDC 63323-972-10
Reason for recall
Labeling Error: Label Error on Declared Strength: Carton label and product insert incorrectly states the quantity of the excipient edetate disodium (EDTA) as 5.4 mg / vial, rather than the actual amount of 18.8 mg / vial.
Distribution pattern
Nationwide within the United States
Code information
Lot #: 6122760, 6122761, exp 08/2021; 6122762, exp 09/2021; 6123883, exp 03/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1391-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026